• PTAB Denies Amgen’s IPR in Win for AbbVie - Article “Suggests a High Degree of Unpredictability” in the Art at Time of Invention
  • February 15, 2016 | Author: Robert H. Resis
  • Law Firm: Banner & Witcoff, Ltd. - Chicago Office
  • The Patent Trial and Appeal Board recently denied institution of Amgen’s inter partes review against an AbbVie patent covering HUMIRA® (currently, the best-selling drug in the world).